Yuyantang’s Entry into Hong Kong Market Signals Strong Growth Potential

Yuyantang, a key player in traditional Chinese medicine, has applied for an IPO in Hong Kong, revealing impressive revenue and profit growth in recent months. The company, founded in 2015 by Guo Yang, has emerged as the fifth-largest private TCM service provider in China, specializing in treating chronic diseases like heart disease, stroke, and diabetes. A distinctive feature of Yuyantang is its dedication to building and operating all its centers, ensuring consistency in clinical protocols, service quality, and brand standards. The company’s core revenue driver has been prescription preparations, accounting for over 90% of its total revenue. Yuyantang’s focus on…